Navigation Links
Microarray Gasket Slide Kit for Hybridization Chamber - SureHyb enabled (11K ) from Agilent Technologies

ProductsMicroarray Gasket Slide Kit for Hybridization Chamber - SureHyb enabled (11K ) from Agilent Technologies
Company Agilent Technologies
Item Microarray Gasket Slide Kit for Hybridization Chamber - SureHyb enabled (11K )
Price 
Description Contents include:
5 gasket slides/kit
  • Gasket slide kit (1x 22K gasket/slide) G2534-60003 or
  • Gasket slide kit (2x 11K gasket/slide) G2534-60002
This unique set of disposable gasket slides offered in either 11K or 22K microarray feature formats, accommodate both Agilent oligo microarray formats. The gaskets are carefully fabricated and batch tested to ensure performance with used in conjunction with Agilent in situ hybridization kit reagents and Agilents precision-engineered stainless steel microarray hybridization chamber.
Info Agilent TechnologiesAgilent Technologies


US and Canada
395 Page Mill Rd.
P.O. Box #10395
Palo Alto, CA 94303
USA

For Agilent contacts in other countries
please click here.

Customer Service: 1-800-227-9770/1-302-993-5304
Web Site: http://www.agilent.com/chem
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. DNA/RNA Aptamer Microarray - Comprehensive Service from LC Sciences
2. Standard Protein Kinase Substrate (PKS) Peptide Microarray from LC Sciences
3. Protein Kinase Substrate (PKS) Peptide Microarray - Comprehensive Service from LC Sciences
4. Small Non-coding RNA Discovery Microarray - Comprehensive Service from LC Sciences
5. Custom 2-OMe RNA Aptamer Microarray from LC Sciences
6. Custom DNA Aptamer Microarray from LC Sciences
7. Epitope Peptide Microarray - Comprehensive Service from LC Sciences
8. Custom 2-F RNA Aptamer Microarray from LC Sciences
9. Custom Peptide Microarray - Comprehensive Service from LC Sciences
10. Standard DNA Aptamer Microarray from LC Sciences
11. Standard 2-F RNA Aptamer Microarray from LC Sciences
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... Reverse Transcriptase (AMV RT) catalyzes the polymerization ... RNA:DNA hybrids (1). It requires a primer ... primers) as well as Mg2+ or Mn2+. ... activity. Both nonionic detergents and sulfhydryl compounds ...
... Stem Cell Expansion Kit - Neurosphere is a ... stem cell expansion as neurospheres in a serum ... N-2 Plus Media Supplement, which has been optimized ... et al . (1996) Genes & Development ...
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
Biology Products:
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... at Northwestern University Feinberg School of Medicine played ... approval of Abraxane (paclitaxel protein-bound particles for injectable ... cancer. "The approval means that women with metastatic ... toxicities associated with solvents and will no longer ...
... Hopkins Medical Institutions in Baltimore, Md., reports that whole-body ... identify new, unexpected malignant cancerous tumors in patients, according ... Society of Nuclear Medicine's Journal of Nuclear Medicine. , ... to have cancer," said SNM member Richard L. Wahl, ...
... and Drug Administration (FDA) was "the single greatest obstacle ... safety officer David Graham at an unprecedented roundtable of ... (PLoS) and the Government Accountability Project. , In comments ... Senate Finance Committee, Graham said that, "Nearly 60,000 people ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2Medical whistleblowers speak out 2Medical whistleblowers speak out 3
(Date:2/27/2015)... and SUMMERLAND, British Columbia , Feb. ... XON ), a leader in synthetic biology, today ... Okanagan Specialty Fruits (OSF), the pioneering agricultural company ... world,s first non-browning apple. Through the acquisition, Intrexon expands ... is more appetizing and convenient for consumers while providing ...
(Date:2/27/2015)... 27, 2015 A paper published today, ... portfolio " in Science Translational Medicine, ... to reduce the risk associated with investing in ... new levels of funding for developing so-called "orphan" ... unique collaboration between scientists at the National Center ...
(Date:2/27/2015)... Scotia (PRWEB) February 27, 2015 ... vaccine and immunotherapy company, today announced that the ... application for Fast Track designation and Phase I ... in conjunction with the mutual co-development agreement signed ... obtained Fast Track designation for the DPX-Survivac. , ...
(Date:2/27/2015)... Bionomics Limited (ASX:BNO, ADR:BMICY) is to present ... in patients with metastatic renal cancer at the ASCO ... . The data will be presented by Dr. ... Cancer Center in California in ... identifies Ferritin and IL-8 as two baseline biomarkers that ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5